Artificial intelligence-based multimodal integration of ultrasound and digital breast tomosynthesis for breast-level risk classification.

Authors

Yujie Tan, Zhenjun Huang, Junwei Li, Ying Zhong, Qinyue Yao, Rui Chen, Yunfang Yu, Yaping Yang, Herui Yao

Published in

Precision clinical medicine. Volume 9. Issue 3. Pages pbag023. Epub Aug 19, 2026.

Abstract

Breast cancer imaging frequently combines ultrasound (US), digital mammography (DM), and digital breast tomosynthesis (DBT), yet integrating complementary findings remains labor-intensive.
We developed a parallel-branch deep learning framework for breast-level risk classification from paired US, DM, and DBT examinations. The models were trained on 2187 breasts and evaluated in an internal validation cohort of 632 breasts and an independent pathology-confirmed cohort of 500 breasts. Six single- and dual-modality models were compared.
In the internal validation cohort, US-DBT achieved the highest observed area under the curve (AUC) of 0.944 (95% CI, 0.926-0.963), exceeding US-DM and DM-DBT but not US; its sensitivity was 0.860 (95% CI, 0.805-0.904) and specificity was 0.904 (95% CI, 0.871-0.930). In the pathology-confirmed cohort, US-DBT achieved an AUC of 0.934 (95% CI, 0.913-0.955), exceeding US and DM-DBT but not US-DM. Its specificity was higher than that of all three models (0.955; 95% CI, 0.927-0.975; all adjusted P < 0.001), with a positive predictive value (PPV) of 0.958 (95% CI, 0.931-0.977) and sensitivity of 0.850 (95% CI, 0.807-0.887), which did not differ significantly from any of the three models. Performance remained favorable in dense breasts, lesions <2 cm, and lower-suspicion Breast Imaging Reporting and Data System (BI-RADS) strata.
These findings identify improved specificity as the principal added value of US-DBT and support its potential use as an adjunctive breast-level tool for refining positive imaging findings and prioritizing further diagnostic evaluation. Prospective validation in representative screening populations is required.

PMID:
42732219
Bibliographic data and abstract were imported from PubMed on 13 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.